Visit-to-visit variability in blood pressure strongly predicts all-cause mortality in patients with type 2 diabetes: A 5·5-year prospective analysis

European Journal of Clinical Investigation

Volumn 42, Issue 3, 2012, Pages 245-253

  Hsieh, Yi Ting ^a,b   Tu, Shih Te ^c   Cho, Tzu Jung ^d   Chang, Shun Jen ^e   Chen, Jung Fu ^f   Hsieh, Ming Chia ^c,g,h  

^a BUDDHIST TZU CHI GENERAL HOSPITAL   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^c CHANGHUA CHRISTIAN HOSPITAL   (Taiwan)

^d CATHAY GENERAL HOSPITAL   (Taiwan)

^e KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^f CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^g CHINA MEDICAL UNIVERSITY   (Taiwan)

^h CHUNG SHAN MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Blood pressure variability; Diabetes; Hypertension; Mortality; Taiwanese

Indexed keywords

ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CREATININE; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; ORAL ANTIDIABETIC AGENT; TRIACYLGLYCEROL;

ADULT; ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE VARIABILITY; BLOOD SAMPLING; BODY MASS; CARDIOVASCULAR RISK; COHORT ANALYSIS; CREATININE BLOOD LEVEL; DIABETIC PATIENT; DIASTOLIC BLOOD PRESSURE; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; HAZARD RATIO; HUMAN; HYPERTENSION; INSULIN TREATMENT; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MEAN ARTERIAL PRESSURE; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBSERVATIONAL STUDY; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PULSE PRESSURE; RISK FACTOR; SYSTOLIC BLOOD PRESSURE;

AGED; ASIAN CONTINENTAL ANCESTRY GROUP; BLOOD PRESSURE; BLOOD PRESSURE DETERMINATION; CARDIOVASCULAR DISEASES; CAUSE OF DEATH; COHORT STUDIES; DIABETES MELLITUS, TYPE 2; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; OFFICE VISITS; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS;

EID: 84856567445     PISSN: 00142972     EISSN: 13652362     Source Type: Journal    
DOI: 10.1111/j.1365-2362.2011.02574.x     Document Type: Article

References (25)

1. UKPDS 38 UK Prospective Diabetes Study 1998 Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes. BMJ 1998;317:703-13.
2. Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the multiple risk factor intervention trial. Diabetes Care 1993;16:434-44.
3. Hansson L, Zanchetti A, Carruthers SG, Dahlof B, Elmfeldt D, Julius S et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension principal results of the hypertension optimal treatment (HOT) randomised trial. HOT study group. Lancet 1998;351:1755-62.
4. Mogensen CE. New treatment guidelines for a patient with diabetes and hypertension. J Hypertens Suppl 2003;21:S25-30.
5. Cooper-DeHoff RM, Gong Y, Handberg EM, Bavry AA, Denardo SJ, Bakris GL et al. Tight blood pressure control and cardiovascular outcomes among hypertensive patients with diabetes and coronary artery disease. JAMA 2010;304:61-8.
6. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R. Age-specific relevance of usual blood pressure to vascular mortality a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002;360:1903-13.
7. Stamler J, Stamler R, Neaton JD. Blood pressure, systolic and diastolic, and cardiovascular risks. US population data. Arch Intern Med 1993;153:598-615.
8. Benetos A, Safar M, Rudnichi A, Smulyan H, Richard JL, Ducimetieere P et al. Pulse pressure a predictor of long-term cardiovascular mortality in a French male population. Hypertension 1997;30:1410-5.
9. Cuffe RL, Howard SC, Algra A, Warlow CP, Rothwell PM. Medium-term variability of blood pressure and potential underdiagnosis of hypertension in patients with previous transient ischemic attack or minor stroke. Stroke 2006;37:2776-83.
10. Turner MJ, van Schalkwyk JM. Blood pressure variability causes spurious identification of hypertension in clinical studies a computer simulation study. Am J Hypertens 2008;21:85-91.
11. Rothwell PM, Howard SC, Dolan E, O'Brien E, Dobson JE, Dahlof B et al. Prognostic significance of visit-to-visit variability, maximum systolic blood pressure, and episodic hypertension. Lancet 2010;375:895-905.
12. Sega R, Corrao G, Bombelli M, Beltrame L, Facchetti R, Grassi G et al. Blood pressure variability and organ damage in a general population results from the PAMELA study (Pressioni Arteriose Monitorate E Loro Associazioni). Hypertension 2002;39:710-4.
13. Sander D, Kukla C, Klingelhofer J, Winbeck K, Conrad B. Relationship between circadian blood pressure patterns and progression of early carotid atherosclerosis A 3-year follow-up study. Circulation 2000;102:1536-41.
14. Kikuya M, Hozawa A, Ohokubo T, Tsuji I, Michimata M, Matsubara M et al. Prognostic significance of blood pressure and heart rate variabilities the Ohasama study. Hypertension 2000;36:901-6.
15. Tozawa M, Iseki K, Yoshi S, Fukiyama K. Blood pressure variability as an adverse prognostic risk factor in end-stage renal disease. Nephrol Dial Transplant 1999;14:1976-81.
16. Hata Y, Kimura Y, Muratani H, Fukiyama K, Kawano Y, Ashida T et al. Office blood pressure variability as a predictor of brain infarction in elderly hypertensive patients. Hypertens Res 2000;23:553-60.
17. Hata Y, Muratani H, Kimura Y, Fukiyama K, Kawano Y, Ashida T et al. Office blood pressure variability as a predictor of acute myocardial infarction in elderly patients receiving antihypertensive therapy. J Hum Hypertens 2002;16:141-6.
18. Pringle E, Phillips C, Thijs L, Davidson C, Staessen JA, de Leeuw PW et al. Systolic blood pressure variability as a risk factor for stroke and cardiovascular mortality in the elderly hypertensive population. J Hypertens 2003;21:2251-7.
19. Stehouwer CD, Henry RM, Ferreira I. Arterial stiffness in diabetes and the metabolic syndrome a pathway to cardiovascular disease. Diabetologia 2008;51:527-39.
20. Nilsson PM, Cederholm J, Eeg-Olofsson K, Eliasson B, Zethelius B, Gudbjornsdottir S. Pulse pressure strongly predicts cardiovascular disease risk in patients with type 2 diabetes from the Swedish national diabetes register (NDR). Diabetes Metab 2009;35:439-46.
21. Bangalore S, Messerli FH, Franklin SS, Mancia G, Champion A, Pepine CJ. Pulse pressure and risk of cardiovascular outcomes in patients with hypertension and coronary artery disease an INternational VErapamil SR-trandolapril STudy (INVEST) analysis. Eur Heart J 2009;30:1395-401.
22. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr et al. Seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension 2003;42:1206-52.
23. Cushman WC, Evans GW, Byington RP, Goff DC, Grimm RH, Cutler JA et al. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med 2010;362:1575-85.
24. Messerli FH, Mancia G, Conti CR, Hewkin AC, Kupfer S, Champion A et al. Dogma disputed can aggressively lowering blood pressure in hypertensive patients with coronary artery disease be dangerous? Ann Intern Med 2006;144:884-93.
25. Berl T, Hunsicker LG, Lewis JB, Pfeffer MA, Porush JG, Rouleau JL et al. Impact of achieved blood pressure on cardiovascular outcomes in the Irbesartan diabetic nephropathy trial. J Am Soc Nephrol 2005;16:2170-9.